erlotinib
Researchers call for more data sharing from single-cell RNA sequencing studies to help validate machine learning precision medicine tools.
The EGFR C797X mutation is the most common on-target resistance mechanism to EGFR TKIs, and drugmakers behind fourth-generation inhibitors are trying to tackle it.
Geneseeq Multi-Biomarker Approach Predicts EGFR-Mutated NSCLC Patients' Adjuvant Therapy Benefit
Premium
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.
Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features
Using a single-cell sequencing and clonal fitness mapping method, researchers compared EGFR-mutant lung cancer cell responses to EGFR inhibition or targeted protein degradation.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.